Science, Access, and Accountability in a Changing Health Landscape

Across health systems, the pace of change in patient care continues to accelerate. As influence over health decisions continues to expand beyond traditional clinical settings, ensuring that credible, evidence-based voices remain central to that conversation has become increasingly important. Pharmacists are increasingly called upon to interpret evolving evidence, navigate shifting policy landscapes, and ensure that patients receive safe, effective care across every setting where medications are used. This responsibility is expanding at a time when the boundaries between innovation, access, and evidence are becoming less clearly defined.

This issue of Pharmacy Practice in Focus: Health Systems reflects that reality. Topics such as deprescribing insulin and optimizing continuous glucose monitoring, advancing pharmacogenomics, and refining antithrombotic management highlight a profession grounded in precision, data, and individualized care. These are active areas where pharmacists are shaping outcomes today.

At the same time, broader conversations across health care are influencing how therapies are evaluated and adopted. National reporting has highlighted increasing attention on emerging therapies, including peptides and other longevity-focused interventions, alongside federal consideration of how these products should be regulated.¹^,² Although these advances continue to evolve, they indicate a wider movement where the demand for innovative therapies is increasing in tandem with persistent initiatives to advance clinical evidence, safety standards, and regulatory systems. Consistent with this approach, the FDA has emphasized that compounded drugs are not FDA approved, meaning their safety, effectiveness, and quality are not verified prior to patient use, and has taken action against non–FDA-approved glucagon-like peptide-1 products in response to similar concerns.³^,⁴ Peer-reviewed analyses further highlight the need for clearer clinical guidance and regulatory alignment as utilization continues to grow.⁵

At the same time, evolving national health guidance has introduced additional complexity across care delivery. Recent public reporting has highlighted ongoing discussions around vaccine recommendations, reinforcing the importance of consistent, evidence-based communication across the health system.⁶ As guidance continues to evolve and is discussed more openly across public and professional settings, patients and providers increasingly look for clarity. Pharmacists are often among the most accessible clinicians positioned to provide that clarity, translating complex and sometimes conflicting information into actionable decisions. This responsibility now extends beyond traditional clinical environments, as many patients are forming health decisions through digital and social platforms. Ensuring that accurate, evidence-based information is represented in these spaces will require pharmacists to engage more actively, bringing clinical expertise into conversations where misinformation can otherwise take hold.

Several emerging trends are further reshaping the practice environment. Clinical decision-making is increasingly influenced by artificial intelligence (AI)–enabled tools that support therapy selection, risk stratification, and workflow efficiency, with a majority of health systems now actively implementing or investing in these capabilities.⁷ As these tools become more embedded in care delivery, pharmacists play a critical role in validating outputs, identifying bias, and ensuring alignment with clinical evidence. More importantly, AI is beginning to go further than individual tools, helping to connect the full scope of pharmacy practice. By integrating data across care settings, AI is supporting pharmacists in moving closer to the center of clinical care, enabling more consistent involvement in chronic disease management across inpatient, ambulatory, and community environments.

This shift also has implications for the profession itself. As roles become more connected through shared data and clinical insight, pharmacists across settings that use AI tools are better positioned to function as a more unified clinical force rather than as isolated points of care. These same capabilities are strengthening collaboration with physicians, providing timelier, data-driven recommendations that support trust and more coordinated decision-making. As these technologies continue to advance, it will be important for the profession to remain actively engaged in their development and application to ensure pharmacists continue to play a central role in shaping their use.

These dynamics reinforce a central principle that access alone does not equal quality, and wellness does not always equate to being well. For health-system pharmacy leaders, this moment requires a clear and disciplined approach. Pharmacists must continue to anchor decision-making in evidence, even as demand for emerging therapies grows. This includes strengthening interdisciplinary collaboration, engaging alongside national and medical organizations in policy discussions, and ensuring that clinical standards evolve alongside innovation. It also requires recognizing the role of pharmacists across all practice settings. Community and retail pharmacies remain essential access points for patients and play a critical role in prevention, chronic disease management, and continuity of care.

Across all of these areas, pharmacists operate at the intersection of science, systems, and patient experience. This role carries increasing responsibility. As health care continues to evolve, pharmacists must remain active participants in shaping how new therapies are evaluated, how care is delivered, and how patients understand their treatment options. Care will continue to evolve, but whether that evolution remains grounded in science will depend on pharmacists stepping forward to sit at the table and lead.

REFERENCES

1. FDA to weigh easing limits on unproven peptides promoted by RFK Jr. NBC News. April 15, 2026. Accessed April 17, 2026. https://www.nbcnews.com/health/health-news/fda-peptides-weighs-loosen-restrictions-longevity-rfk-jr-rcna332011

2. Stone W. The wellness world is eager for RFK Jr.’s promised move on peptides. NPR. March 31, 2026. Accessed April 1, 2026. https://www.npr.org/2026/03/31/nx-s1-5768206/peptides-rfk-fda-compounding-pharmacies

3. Compounding and the FDA: questions and answers. FDA. Updated September 16, 2025. Accessed April 1, 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

4. FDA intends to take action against non-FDA-approved GLP-1 drugs. News release. FDA. February 6, 2026. Accessed April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs

5. Bays HE, Fitch A, Francavilla Brown C, Younglove C, Christensen SM, Alexander LC. Frequently asked questions to the 2023 Obesity Medicine Association position statement on compounded peptides: a call for action. Obes Pillars. 2024;11:100122. doi:10.1016/j.obpill.2024.100122

6. Schreiber M. Uncharted territory: uncertainty as US vaccine guidance falls apart under Trump. Guardian. April 15, 2026. Accessed April 17, 2026. https://www.theguardian.com/us-news/2026/apr/15/uncertainty-vaccine-guidance-trump-administration

7. 2025 global health care outlook. Deloitte Center for Health Solutions. January 29, 2025. Accessed April 1, 2026. https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-global-health-care-executive-outlook.html